AbbVie’s Skyrizi combo beats Skyrizi alone in mid-stage Crohn’s trial
AbbVie’s Skyrizi-based combination therapy for inflammatory bowel disease worked better than Skyrizi alone in a mid-stage trial in Crohn’s disease, the company said Monday. The new product is codenamed ABBV-466 and combines Skyrizi, an IL-23 ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.